Abstract
Hodgkin Lymphoma (HL) represents one of the most common types of a non-AIDS-defining tumour that occurs in the HIV population, and its incidence is increasing in the post Highly Active Anti-retroviral Therapy (HAART) era. Despite the aggressiveness of that disease, the outcome of patients with HIV-HL has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs, in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HL with chemotherapy. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HL may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. In addition, new functional imaging tools, like the Positron Emission Tomography (PET), may help to guide treatment and minimize long term toxicity.
Keywords: Hodgkin lymphoma, HIV, non-AIDS-defining tumour, chemotherapy
Current HIV Research
Title: Hodgkin Lymphoma in HIV Positive Patients
Volume: 8 Issue: 2
Author(s): Nicolas Mounier, Michele Spina and Jean P. Spano
Affiliation:
Keywords: Hodgkin lymphoma, HIV, non-AIDS-defining tumour, chemotherapy
Abstract: Hodgkin Lymphoma (HL) represents one of the most common types of a non-AIDS-defining tumour that occurs in the HIV population, and its incidence is increasing in the post Highly Active Anti-retroviral Therapy (HAART) era. Despite the aggressiveness of that disease, the outcome of patients with HIV-HL has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs, in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HL with chemotherapy. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HL may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. In addition, new functional imaging tools, like the Positron Emission Tomography (PET), may help to guide treatment and minimize long term toxicity.
Export Options
About this article
Cite this article as:
Mounier Nicolas, Spina Michele and Spano P. Jean, Hodgkin Lymphoma in HIV Positive Patients, Current HIV Research 2010; 8 (2) . https://dx.doi.org/10.2174/157016210790442704
DOI https://dx.doi.org/10.2174/157016210790442704 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Inclusion Complexes of Halide Anions with Macrocyclic Receptors
Current Organic Chemistry CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Solid Lipid Nanoparticles and Nanostructured Lipid Carriers – Innovative Generations of Solid Lipid Carriers
Current Drug Delivery Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study
Current Radiopharmaceuticals Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Current Drug Targets Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Role of the Bone Marrow Microenvironment in Drug Resistance of Hematological Malignances
Current Medicinal Chemistry Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research Molecular Biology of the Enzymes that Degrade Endocannabinoids
Current Drug Targets - CNS & Neurological Disorders Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies
Current Drug Targets